English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/217715
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

SARS-Cov-2 cysteine-like protease (Mpro) is immunogenic and can be detected in serum and saliva of COVID-19-seropositive individuals

Other TitlesSARS-CoV-2 protease antibodies in serum and saliva
AuthorsMartinez-Fleta, Pedro; Alfranca, Arántzazu; González-Álvaro, Isidoro; Casasnovas, José María ; Fernández-Soto, Daniel; Esteso, Gloria; Cáceres-Martell, Yaiza; Gardeta, Sofía; Prat, Salomé; Mateu-Alberoa, Tamara; Gabrie, Ligia; López-Granados, Eduardo; Sánchez-Madrid, Francisco; Rodríguez-Frade, José Miguel; Reyburn, H. T. ; Valés-Gómez, Mar
KeywordsCoronavirus
Diagnostics
Serology
COVID-19
ELISA
Issue Date18-Jul-2020
PublisherMedRxiv
AbstractCurrently, there is a need for reliable tests that allow identification of individuals that have been infected with SARS-CoV-2 even if the infection was asymptomatic. To date, the vast majority of the serological tests for SARS-CoV-2 specific antibodies are based on serum detection of antibodies to either the viral spike glycoprotein (the major target for neutralising antibodies) or the viral nucleocapsid protein that are known to be highly immunogenic in other coronaviruses. Conceivably, exposure of antigens released from infected cells could stimulate antibody responses that might correlate with tissue damage and, hence, they may have some value as a prognostic indicator. We addressed whether other non-structural viral proteins, not incorporated into the infectious viral particle, specifically the viral cysteine-like protease, might also be potent immunogens. Using ELISA tests, coating several SARS-CoV-2 proteins produced in vitro, we describe that COVID-19 patients make high titre IgG, IgM and IgA antibody responses to the Cys-like protease from SARS-CoV-2, also known as 3CLpro or Mpro, and it can be used to identify individuals with positive serology against the coronavirus. Higher antibody titres in these assays associated with more severe disease and no cross-reactive antibodies against prior betacoronavirus were found. Remarkably, IgG antibodies specific for Mpro and other SARS-CoV-2 antigens can also be detected in saliva. In conclusion, Mpro is a potent antigen in infected patients that can be used in serological tests and its detection in saliva could be the basis for a rapid, non-invasive test for COVID-19 seropositivity.
Publisher version (URL)https://doi.org/10.1101/2020.07.16.20155853
URIhttp://hdl.handle.net/10261/217715
DOI10.1101/2020.07.16.20155853
Appears in Collections:(CNB) Artículos
(VICYT) Colección Especial COVID-19
Files in This Item:
File Description SizeFormat 
SARS-Cov-2 cysteine-like protease.pdf2,94 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.